ABT
Abbott Laboratories
Income statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.2B | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B | 34.6B | 31.9B | 30.6B | 27.4B | 20.9B | 20.4B | 20.2B | 19.7B | 19.1B | 21.4B | 35.2B | 30.8B | 29.5B | 25.9B |
Cost of revenue | 20.8B | 19.3B | 18.7B | 18.0B | 19.1B | 18.5B | 15.0B | 13.2B | 12.7B | 12.4B | 9.1B | 8.7B | 9.2B | 9.2B | 8.9B | 10.0B | 14.7B | 13.2B | 12.6B | 11.4B |
| Gross profit | 27.5B | 25.0B | 23.2B | 22.1B | 24.5B | 24.5B | 19.6B | 18.7B | 17.9B | 15.0B | 11.8B | 11.7B | 11.0B | 10.5B | 10.2B | 11.4B | 20.5B | 17.6B | 16.9B | 14.5B |
| 3.31B | 2.94B | 2.84B | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.26B | 1.45B | 1.41B | 1.35B | 1.37B | 1.46B | 1.51B | 3.72B | 2.74B | 2.69B | 2.51B | |
| 15.2B | 12.3B | 11.7B | 10.9B | 11.2B | 11.3B | 9.7B | 9.8B | 9.7B | 9.2B | 6.7B | 6.8B | 6.5B | 6.4B | 6.7B | 7.4B | 10.4B | 8.4B | 8.4B | 7.4B | |
Other operating expenses | 2.34B | 1.68B | 1.88B | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 2.18B | 1.98B | 0.55B | 0.60B | 0.56B | 0.59B | 0.60B | 0.88B | 0.31B | 0.17B | 97M | — |
| Operating income | 6.65B | 8.05B | 6.83B | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.56B | 3.03B | 2.87B | 2.60B | 2.13B | 1.36B | 1.63B | 6.09B | 6.24B | 5.69B | 4.58B |
Non-operating income | −85M | 0.41B | 0.19B | 0.19B | −56M | −0.21B | −0.39B | −0.46B | −0.78B | 0.67B | −1.61B | 0.32B | −81M | −92M | −1.58B | −0.39B | −0.37B | 0.96B | — | — |
| Pretax income | 6.56B | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.04B | −0.22B | 1.24B | 5.71B | 7.19B | — | — |
Taxes | 1.86B | 1.94B | −6.39B | 0.94B | 1.37B | 1.14B | 0.47B | 0.39B | 0.51B | 1.75B | 13M | −1.24B | 0.23B | −0.54B | −6.18B | −3.49B | 1.09B | 1.45B | — | — |
| Net income | 4.7B | 6.5B | 13.4B | 5.7B | 6.9B | 7.1B | 4.5B | 3.7B | 2.4B | 477M | 1.4B | 4.4B | 2.3B | 2.6B | 6.0B | 4.7B | 4.6B | 5.7B | 4.9B | 3.6B |
| Diluted EPS | 2.70 | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 | 1.49 | 1.62 | 3.72 | 3.01 | 2.96 | 3.69 | 3.12 | 2.31 |
| Diluted shares | — | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B |
| Revenue growth | — | +5.7% | +4.6% | −8.1% | +1.3% | +24.5% | +8.5% | +4.3% | +11.6% | +31.3% | +2.2% | +0.8% | +3.0% | +3.2% | −11.0% | −39.1% | +14.3% | +4.2% | +13.9% | — |
| Gross margin | 56.9% | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | 56.6% | 58.5% | 58.4% | 54.7% | 56.4% | 57.1% | 54.5% | 53.2% | 53.3% | 53.2% | 58.3% | 57.1% | 57.3% | 55.9% |
| Operating margin | 13.8% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | 15.5% | 14.2% | 11.9% | 5.7% | 14.5% | 14.1% | 12.8% | 10.9% | 7.1% | 7.6% | 17.3% | 20.3% | 19.3% | 17.7% |
| Net margin | 9.7% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% | 11.3% | 13.1% | 31.3% | 22.1% | 13.2% | 18.7% | 16.5% | 13.9% |